PRMT1 and plasma cell myeloma: Accordingly, pharmacological inhibition of PRMT1 with compounds such as MS023 directly eliminates multiple myeloma cells and synergizes with immunotherapy, presenting a novel therapeutic strategy for refractory disease [76].